Simultaneous determination of AZD1152 (prodrug) and AZD1152-hydroxyquinazoline pyrazol anilide by reversed phase liquid chromatography

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 877, Issue 29, 2009, Pages 3549-3555

  Pluim, Dick ^a   Beijnen, Jos H ^a,b   Schellens, Jan H M ^a,b,c   van Tellingen, Olaf ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c Science Faculty   (Netherlands)

Author keywords

AZD1152; AZD1152 hydroxyquinazoline pyrazol anilide; HPLC; hQPA; Human; Mouse; Plasma; Tissues

Indexed keywords

AZD1152; EX-VIVO; HUMAN PLASMAS; ISOCRATIC SEPARATION; LOWER LIMIT OF QUANTIFICATIONS; MOBILE PHASE; MOUSE PLASMA; MOUSE TISSUES; PRODRUGS; PROTEIN PRECIPITATION; REVERSED PHASE LIQUID-CHROMATOGRAPHY; SAMPLE PREPARATION; SIMULTANEOUS DETERMINATIONS; SINGLE-STEP; SODIUM FLUORIDE; ULTRA VIOLET DETECTION; UV DETECTION; VALIDATION PARAMETERS;

ACETONITRILE; CHROMATOGRAPHIC ANALYSIS; CHROMATOGRAPHY; ETHANOL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH PRESSURE LIQUID CHROMATOGRAPHY; HISTOLOGY; LIQUIDS; PLASMA (HUMAN); SODIUM; ULTRAVIOLET DETECTORS;

PLASMAS;

2 [[3 [4 [5 [2 (3 FLUOROANILINO) 2 OXOETHYL] 1H PYRAZOL 3 YLAMINO] 7 QUINAZOLINYLOXY]PROPYL](ETHYL)AMINO]ETHYL DIHYDROGEN PHOSPHATE; ALCOHOL; AZD 1152 HYDROXYQUINAZOLINE PYRAZOL ANILIDE; METHOTREXATE; PHOSPHATASE; PRODRUG; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHEMICAL STRUCTURE; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DETERMINATION; DRUG LIVER LEVEL; ENZYME ACTIVITY; EXTRACTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; ILEUM; KIDNEY; MOUSE; NONHUMAN; PLASMA; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; TISSUE DISTRIBUTION; VALIDATION STUDY;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; HYDROXYQUINOLINES; MICE; MOLECULAR STRUCTURE; PHOSPHORIC ACID ESTERS; PYRAZOLES; QUINAZOLINES; REPRODUCIBILITY OF RESULTS;

MUS;

EID: 72049118879     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchromb.2009.08.035     Document Type: Article

References (21)

1. Adams R.R., Carmena M., and Earnshaw W.C. Trends Cell Biol. 11 (2001) 49
2. Andrews P.D., Knatko E., Moore W.J., and Swedlow J.R. Curr. Opin. Cell Biol. 15 (2003) 672
3. Ditchfield C., Johnson V.L., Tighe A., Ellston R., Haworth C., Johnson T., Mortlock A., Keen N., and Taylor S.S. J. Cell Biol. 161 (2003) 267
4. Goto H., Yasui Y., Nigg E.A., and Inagaki M. Genes Cells 7 (2002) 11
5. Carmena M., and Earnshaw W.C. Nat. Rev. Mol. Cell Biol. 4 (2003) 842
6. Girdler F., Gascoigne K.E., Eyers P.A., Hartmuth S., Crafter C., Foote K.M., Keen N.J., and Taylor S.S. J. Cell Sci. 119 (2006) 3664
7. Mortlock A.A., Foote K.M., Heron N.M., Jung F.H., Pasquet G., Lohmann J.J., Warin N., Renaud F., De Savi C., Roberts N.J., Johnson T., Dousson C.B., Hill G.B., Perkins D., Hatter G., Wilkinson R.W., Wedge S.R., Heaton S.P., Odedra R., Keen N.J., Crafter C., Brown E., Thompson K., Brightwell S., Khatri L., Brady M.C., Kearney S., McKillop D., Rhead S., Parry T., and Green S. J. Med. Chem. 50 (2007) 2213
8. Wilkinson R.W., Odedra R., Heaton S.P., Wedge S.R., Keen N.J., Crafter C., Foster J.R., Brady M.C., Bigley A., Brown E., Byth K.F., Barrass N.C., Mundt K.E., Foote K.M., Heron N.M., Jung F.H., Mortlock A.A., Boyle F.T., and Green S. Clin. Cancer Res. 13 (2007) 3682
9. Chen C.J., Chin J.E., Ueda K., Clark D.P., Pastan I., Gottesman M.M., and Roninson I.B. Cell 47 (1986) 381
10. Cole S.P., Bhardwaj G., Gerlach J.H., Mackie J.E., Grant C.E., Almquist K.C., Stewart A.J., Kurz E.U., Duncan A.M., and Deeley R.G. Science 258 (1992) 1650
11. Seamon J.A., Rugg C.A., Emanuel S., Calcagno A.M., Ambudkar S.V., Middleton S.A., Butler J., Borowski V., and Greenberger L.M. Mol. Cancer Ther. 5 (2006) 2459
12. Allen J.D., Brinkhuis R.F., Wijnholds J., and Schinkel A.H. Cancer Res. 59 (1999) 4237
13. Doyle L.A., Yang W., Abruzzo L.V., Krogmann T., Gao Y., Rishi A.K., and Ross D.D. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 15665
14. Miyake K., Mickley L., Litman T., Zhan Z., Robey R., Cristensen B., Brangi M., Greenberger L., Dean M., Fojo T., and Bates S.E. Cancer Res. 59 (1999) 8
15. Ross D.D., Yang W., Abruzzo L.V., Dalton W.S., Schneider E., Lage H., Dietel M., Greenberger L., Cole S.P., and Doyle L.A. J. Natl. Cancer Inst. 91 (1999) 429
16. de Vries N.A., Zhao J., Kroon E., Buckle T., Beijnen J.H., and van Tellingen O. Clin. Cancer Res. 13 (2007) 6440
17. Maliepaard M., Scheffer G.L., Faneyte I.F., van Gastelen M.A., Pijnenborg A.C., Schinkel A.H., van De Vijver M.J., Scheper R.J., and Schellens J.H. Cancer Res. 61 (2001) 3458
18. Ma J., Stoter G., Verweij J., and Schellens J.H. Cancer Chemother. Pharmacol. 38 (1996) 391
19. European Pharmacopoeia 4th edition (Ph.Eur.4), Council of Europe, Strasbourg 2001, Chromatographic Separation Techniques (2. 2. 46.), 62 (2001) 61.
20. International Conference on Harmonization (ICH) and Q2A: Text on Validation of Analytical Procedures, US FDA Federal Register, 60 (1995) 11260.
21. International Conference on Harmonization (ICH) and Q2B: Validation of Analytical Procedures: Methodology, US FDA Federal Register, 62 (1997) 27463.